Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia

Acta Haematologica

Volumn 127, Issue 2, 2012, Pages 63-71

  Park, Borae G ^a   Chi, Hyun Sook ^a   Park, Seo Jin ^b   Min, Sook Kyoung ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a   Kim, Dae Young ^a   Lee, Jung Hee ^a   Lee, Je Hwan ^a   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; FLT3; Nucleophosmin; Prognosis

Indexed keywords

FLT3 LIGAND; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; REMISSION INDUCTION; REPUBLIC OF KOREA;

EID: 81355134992     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000331509     Document Type: Article

References (29)

1. Frohling S, Scholl C, Gilliland DG, Levine RL: Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005; 23: 6285-6295. (Pubitemid 46218838)
2. Mrozek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115-136. (Pubitemid 38380667)
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
4. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
5. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020. (Pubitemid 43726809)
6. Koh Y, Park J, Bae EK, Ahn KS, Kim I, Bang SM, Lee JH, Yoon SS, Lee DS, Lee YY, Park S, Kim BK: Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. Int J Hematol 2009; 90: 1-5.
7. Ahmad F, Mandava S, Das BR: Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest 2010; 28: 63-73.
8. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S: Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 2008; 111: 2527-2537.
9. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434-2439. (Pubitemid 32291491)
10. Kim HJ: Mutations in AML with a normal karyotype: NPM1 and FLT3-ITD, ready to use as a key prognosticator? Korean J Hematol 2010; 45: 79-80.
11. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N, Naoe T: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854-2861. (Pubitemid 41510764)
12. Suzuki R, Onizuka M, Kojima M, Shimada M, Okamura K, Fukagawa S, Tsuboi K, Kikuchi A, Kobayashi H, Shintani A, Ogawa Y, Kawada H, Hotta T, Ando K: Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. Int J Hematol 2007; 86: 422-428.
13. Lee JH, Choi SJ, Park JH, Kim H, Joo YD, Lee WS, Zang DY, Kim HJ, Lee KH: Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. Ann Hematol 2006; 85: 357-365.
14. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819. (Pubitemid 20148273)
15. Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM: A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 2008; 142: 489-492. (Pubitemid 351962181)
16. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
17. Rau R, Brown P: Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009; 27: 171-181.
18. Lee KH, Choi SJ, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Yun SC, Joo YD, Lee WS, Kang MJ, Kim H, Park JH, Bae SH, Ryoo HM, Kim MK, Hyun MS: Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated donors. Am J Hematol 2011; 86: 399-405.
19. Boonthimat C, Thongnoppakhun W, Auewarakul CU: Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations. Haematologica 2008; 93: 1565-1569.
20. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Lowenberg B, Valk PJ: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747-3754. (Pubitemid 41739008)
21. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739. (Pubitemid 41739006)
22. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740-3746. (Pubitemid 41739007)
23. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC: The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
24. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)
25. Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Fritsch S, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K: NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009; 113: 5250-5253.
26. Falini B, Sportoletti P, Martelli MP: Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009; 21: 573-581.
27. Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C: Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007; 109: 2264-2265, author reply 2265. (Pubitemid 46348234)
28. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
29. Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P, Pandolfi PP: The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 2007; 26: 7391-7400. (Pubitemid 350158712)